Biomea Fusion Completes Diabetes Trial Enrollment, Reports BMF-650 Results

Biomea Fusion completed enrollment in Phase II COVALENT-211 and reported first-in-human BMF-650 results, including weight reduction and limited Grade 1 GI side effects at the highest dose.